Related by context. All words. (Click for frequent words.) 73 prognostic indicators 70 multivariate analyzes 70 tumor histology 69 histological subtype 69 prostate cancer CaP 69 prognostic factors 68 biochemical recurrence 68 HER2 expression 68 prostate cancer PCa 68 pancreatic adenocarcinoma 67 multivariate regression analysis 67 Logistic regression 67 liver metastasis 67 histologic subtype 67 Zevalin consolidation 67 p# biomarker 66 locoregional 66 angiographically 66 prospective multicenter study 66 prospectively defined 66 clinically localized prostate 66 urothelial carcinoma 66 KRAS status 66 prognostic significance 66 oncologic outcomes 66 HSCT 66 Multiple logistic regression 66 adjuvant therapies 66 multivariate logistic regression 66 renal tumors 66 FDG PET imaging 66 univariate 66 exploratory endpoints 66 Multivariate logistic regression 66 antiangiogenic therapy 66 colorectal liver metastases 66 EGFR mutation status 66 nodal metastasis 65 logistic regression models 65 prognostic biomarker 65 clinicopathological features 65 nomograms 65 juvenile idiopathic arthritis 65 carotid stenosis 65 acetabular fractures 65 Prognostic factors 65 pain palliation 65 autonomic dysfunction 65 T1a 65 comorbidities 65 preoperative chemotherapy 65 postoperative complication 65 CTEPH 65 PNH patients 65 microsatellite instability 65 F FDG PET 65 CIN2 + 65 urothelial cancer 65 clinicopathologic 65 FDG PET 65 PCa 65 covariate 64 myocardial viability 64 HNSCC 64 System IPSS 64 pharmacodynamic parameters 64 diabetes mellitus DM 64 radiotherapy RT 64 epithelial tumors 64 KRAS mutation 64 prostate carcinoma 64 neurocognitive function 64 urolithiasis 64 echocardiographic parameters 64 genomic biomarker 64 ADVEXIN therapy 64 NMIBC 64 multivariable analysis 64 HRQL 64 nodal metastases 64 distant metastasis 64 PROLARIS 64 APOE genotype 64 electrophysiologic 64 perfusion abnormalities 64 clinicopathological 64 ischemic cardiomyopathy 64 nonmetastatic 64 recurrent glioblastoma multiforme 64 T2DM 64 Meta analyzes 64 BEXXAR Therapeutic Regimen 64 haematologic 64 gastric adenocarcinoma 64 hematopoietic cancers 64 postoperative mortality 64 cytologic 64 symptomatic VTE 64 prespecified secondary 64 retrospective cohort 64 histologies 64 multivariate Cox 64 genotypic resistance 64 papillary renal cell carcinoma 64 histological subtypes 64 lymphadenectomy 64 comorbid conditions 64 neurocognitive impairment 64 risk stratification 63 subclinical atherosclerosis 63 graft dysfunction 63 histopathologic 63 Subgroup analyzes 63 etiologic 63 preoperative PSA 63 conditional logistic regression 63 Renal Cell Carcinoma RCC 63 T1DM 63 baseline LDH 63 thromboembolic complications 63 diagnostic modality 63 androgen deprivation 63 Subgroup analysis 63 percutaneous biopsy 63 secondary efficacy endpoint 63 hepatic lesions 63 advanced adenomas 63 intravesical therapy 63 K ras mutations 63 chemoprevention trials 63 adjuvant therapy 63 stratifying patients 63 taxane therapy 63 mammographic density 63 meta regression 63 univariate analyzes 63 angiographic outcomes 63 genomic alterations 63 distant metastases 63 epithelial ovarian cancer 63 Kaplan Meier analysis 63 troponins 63 HIV HCV coinfected 63 intraobserver 63 PROactive study 63 thoracoscopic lobectomy 63 coronary stenosis 63 perioperative morbidity 63 pathophysiological mechanisms 63 surrogate endpoint 63 chemoembolization 63 logistic regression analyzes 63 cervical carcinoma 63 atherothrombotic 63 completely resected 63 pulmonary nodules 63 oncological outcomes 63 randomized controlled trials RCTs 63 acute leukemias 63 breast carcinoma 63 Hepatocellular Carcinoma HCC 63 systolic dysfunction 63 lymph node metastasis 63 mRCC 63 carcinoid tumors 63 differential gene expression 63 logistic regression analysis 63 #F FDG PET 63 hepatorenal syndrome 63 chronic periodontitis 63 postoperative pulmonary 63 histologic 63 postoperative radiotherapy 63 preoperative diagnosis 63 FDG-PET/CT 63 genetic polymorphisms 63 virological response 63 TNF antagonist 63 colorectal adenoma 63 obstructive coronary artery 63 femoral neck fracture 63 operable breast cancer 62 postoperative AF 62 gastric carcinoma 62 postoperative chemotherapy 62 relapsed MM 62 SYNTAX trial 62 hsCRP levels 62 chemosensitivity 62 curative resection 62 psychiatric comorbidity 62 nonalcoholic steatohepatitis NASH 62 elevated LDH 62 prognostically 62 subgroup analyzes 62 metastatic lymph nodes 62 myeloproliferative diseases 62 sleeve lobectomy 62 CP CPPS 62 liver transplant recipients 62 therapeutic regimens 62 esophageal carcinoma 62 cytoreductive nephrectomy 62 PSADT 62 multivessel disease 62 NIHSS score 62 liver histology 62 intima media thickness 62 differentiated thyroid 62 Lymph node 62 symptomatic paroxysmal AF 62 carotid IMT 62 FDG uptake 62 clinico pathological 62 Surgical resection 62 advanced adenoma 62 Venous thromboembolism 62 prognostic markers 62 invasive candidiasis 62 mycosis fungoides 62 T1c 62 Radical prostatectomy 62 underwent resection 62 colonoscopic 62 pelvic lymphadenectomy 62 adrenalectomy 62 pretest probability 62 node metastases 62 stenoses 62 allogeneic transplant 62 cytoreductive surgery 62 FDG PET scans 62 cardiac dysfunction 62 metastatic lung cancer 62 Tumor Response 62 prospective longitudinal 62 follicular lymphoma FL 62 breast cancer subtypes 62 gefitinib Iressa 62 dyslipidaemia 62 radical cystectomy 62 DSM IV diagnoses 62 intact parathyroid hormone 62 viral kinetics 62 renal biopsy 62 locoregional recurrence 62 proliferative retinopathy 62 patient subpopulations 62 Cystatin C 62 pCR 62 adjuvant systemic 62 resectable 62 adverse cytogenetics 62 lymph node involvement 62 Kaplan Meier curves 62 MDRD equation 62 Multivariate analysis 62 antithrombotic therapy 62 malignant pleural mesothelioma 62 metabolic parameters 62 nonrandomized 62 relapsed AML 62 cranial irradiation 62 Stage IIIb 62 patients undergoing CABG 62 demyelinating 62 HER2 positive metastatic breast 62 β blockers 62 pericardial effusion 62 Poisson regression 62 transrectal ultrasound guided 61 mucinous 61 prespecified 61 inflammatory biomarkers 61 renal cysts 61 adenomatous 61 venous thromboembolic disease 61 malignant nodules 61 radiographic findings 61 coronary artery stenosis 61 HIV tropism 61 neratinib 61 RE LY ® 61 ABCB1 61 atherothrombosis 61 pT3 61 BCR ABL mutations 61 ImmuKnow 61 oral anticoagulation 61 ultrasonographic 61 antiangiogenic agents 61 renal scarring 61 invasive aspergillosis 61 adenoma recurrence 61 riociguat 61 macroalbuminuria 61 pretransplant 61 NATRECOR ® 61 intra abdominal abscess 61 artery stenosis 61 dosimetric 61 POAG 61 nonischemic 61 glomerular filtration 61 covariates 61 comorbidity 61 CORE OM 61 prospective multicentre 61 Adjuvant chemotherapy 61 thyroid nodules 61 HGPIN 61 EUS FNA 61 differentiate squamous 61 antiplatelet therapies 61 radical prostatectomy RP 61 ADPKD 61 axillary lymph nodes 61 imatinib therapy 61 hormone receptor status 61 Genetic variants 61 biopsy Gleason 61 basal cell carcinoma BCC 61 interobserver 61 plain radiographs 61 hamartomas 61 elevated IOP 61 decompensated cirrhosis 61 IV NSCLC 61 metastatic RCC 61 ependymoma 61 histopathologic examination 61 tumor subtype 61 cardioembolic stroke 61 bronchopulmonary dysplasia BPD 61 hypercoagulable 61 nonalcoholic steatohepatitis 61 prognostic marker 61 hepatocellular carcinomas 61 metastatic lesions 61 pharmacodynamic markers 61 QTc prolongation 61 confounding variables 61 DNA methylation patterns 61 histologically confirmed 61 binary logistic regression 61 recurrent DVT 61 radiochemotherapy 61 biliary tract cancer 61 smoldering myeloma 61 SSc 61 multivariable analyzes 61 tumor recurrence 61 invasive ductal breast cancer 61 cTnT 61 eTag assays 61 carotid artery stenosis 61 tumor subtypes 61 atherosclerotic disease 61 conformal radiotherapy 61 preoperative staging 61 prognostic indicator 61 International Prognostic Scoring 61 GnRH agonists 61 proliferative diabetic retinopathy 61 thyroid carcinoma 61 prospectively randomized 61 AGHD 61 R0 resection 61 chemoradiotherapy 61 neoadjuvant chemotherapy 61 MMSE score 61 logistic regression model 61 post thrombotic syndrome 61 antiarrhythmic drug 61 surrogate markers 61 CSF biomarkers 61 EuroSCORE 61 Logistic regression analysis 61 VADT 61 intracranial stenosis 61 Heavy menstrual bleeding 61 histologic findings 61 concomitant medications 61 bladder carcinoma 61 radiographic outcomes 61 polyarticular 61 nonsmall cell lung cancer 61 PITX2 61 BR.# 61 upper gastrointestinal bleeding 61 pulmonary dysfunction 61 preserved ejection fraction 61 neoadjuvant therapy 61 lymph node metastases 61 neurodevelopmental outcome 61 gadolinium enhanced 61 de novo AML 61 intra arterial 61 TNM staging 61 carcinoids 61 postoperative atrial fibrillation 60 lung resections 60 lipid lowering agents 60 co morbidities 60 coinfected patients 60 neoadjuvant treatment 60 hemodialysis patients 60 Carotid Revascularization Endarterectomy vs. 60 Thrombolysis 60 bivariate analysis 60 comorbid depression 60 histopathological 60 ductal adenocarcinoma 60 EBRT 60 MDRD 60 endometrial carcinoma 60 antithrombotic agents 60 tumor necrosis 60 incomplete revascularization 60 chest radiographs 60 periprocedural 60 colorectal cancer CRC 60 STRIDE PD 60 Chronic lymphocytic leukemia 60 SCr 60 smoldering multiple myeloma 60 Y BOCS 60 extracranial 60 hepatocellular carcinoma 60 perioperative mortality 60 metastatic renal cell carcinoma 60 percutaneous vertebroplasty 60 Hurthle cell 60 LV dysfunction 60 sociodemographic characteristics 60 hepatic cirrhosis 60 skeletal metastases 60 pulmonary metastases 60 locoregional disease 60 Doxil ® 60 NYHA functional class 60 predictive validity 60 coronary revascularization 60 undergoing coronary angiography 60 interobserver reliability 60 leiomyomas 60 preintervention 60 external beam radiotherapy 60 D dimer 60 debulking surgery 60 choroidal neovascularization 60 SLNB 60 inhaled corticosteroid therapy 60 SHPT 60 multiple logistic regression 60 histologic diagnosis 60 malignant lesions 60 cervical lymph nodes 60 TOP2A 60 scintigraphic 60 resected pancreatic cancer 60 nodal dissection 60 carotid plaques 60 recurrent GBM 60 unmeasured confounders 60 neoplastic lesions 60 brain metastases 60 confounder 60 Vectibix monotherapy 60 Estrogen Receptor 60 prognostic factor 60 PCNSL 60 PROSTVAC TM 60 primary aldosteronism 60 MADIT CRT trial 60 esophagogastric 60 biochemical relapse 60 nephron sparing surgery 60 pulmonary resection 60 BARI 2D 60 unresectable tumors 60 Multivariable logistic regression 60 hepatocellular carcinoma HCC 60 NPM1 mutation 60 FFR measurements 60 neovascular 60 axillary lymph node 60 MGUS 60 definite stent thrombosis 60 pre operatively 60 invasive carcinoma 60 Oncotype DX Recurrence Score 60 hepatic fibrosis 60 hepatic arterial 60 spiral computed tomography 60 Coronary Artery Bypass Graft 60 warfarin dosage 60 nonoperative 60 adenomatous polyps 60 lactate dehydrogenase LDH 60 postintervention 60 epithelial ovarian 60 lymph node dissection 60 acute GvHD 60 plasma pharmacokinetics 60 arteriography 60 invasive lobular carcinoma 60 primary hyperparathyroidism 60 pathologic fractures 60 serum biomarkers 60 tissue oxygenation 60 ICD therapy 60 hormone receptor negative 60 malignant neoplasm 60 spirometric 60 gastroduodenal 60 hENT1 60 psychiatric comorbidities 60 PITX2 methylation 60 KRAS mutation status 60 longitudinal cohort study 60 EQ 5D 60 platelet reactivity 60 periprocedural MI 60 estimated glomerular filtration 60 narrow QRS 60 Cardiotoxicity 60 galiximab 60 EGFR HER2 60 BRAF V#E mutation 60 morphometric vertebral fractures 60 neovascular glaucoma 60 Myelodysplastic syndromes MDS 60 nondiabetic patients 60 recurrent NSCLC 60 NNT = 60 MGd 60 somatic mutations 60 sonographic diagnosis 60 ovarian malignancy 60 nonfatal MI 60 lymphovascular invasion 60 standard chemotherapy regimen 60 obstructive CAD 60 ICD implantation 60 composite endpoint 60 carotid artery narrowing 60 bone scintigraphy 60 atherosclerotic renal artery stenosis 60 Kaplan Meier curve 60 postdischarge 60 subtrochanteric 60 ovarian carcinoma 60 Randomized clinical trials 60 BPS IC 60 clevidipine 60 bronchogenic carcinoma 60 transcranial Doppler 60 candidemia 60 chemotherapeutic regimens 60 Recurrence Score 60 cystectomy 60 allogeneic HSCT 60 gastrointestinal malignancies 60 liver resection 60 IV bisphosphonates 60 hyperoxaluria 60 vertebral fracture 60 specific antigen PSA 60 multivariable logistic regression 60 Sentinel Lymph Node Biopsy 60 inhibitor RG# 60 eosinophilic pneumonia 60 Src inhibitors 60 Histologic 60 ASCUS 60 conventional angiography 60 multicentric 60 HBeAg negative 60 cerebral angiography 60 ipsilateral breast 60 predictive biomarker 60 immunocompetent 60 advanced neoplasia 60 serum PTH 60 secondary hyperparathyroidism 60 extracolonic findings 60 hypoperfusion 60 non squamous NSCLC 60 sociodemographic factors 60 RE LY trial 60 depressive symptomatology 60 chronic myocardial ischemia 60 Prognostic 60 TKI therapy 60 KRAS mutations 60 dyssynchrony 60 cervical intraepithelial neoplasia 60 micrometastasis 60 metastatic malignant melanoma 60 diabetic kidney 60 monoclonal gammopathy 60 androgen suppression 60 transthoracic 60 hepatectomy 60 NATRECOR R 60 Teriflunomide 60 leukocyte count 60 cranial radiation 60 prostate adenocarcinoma 60 neutropaenia 60 myocardial ischemia 60 MACCE 60 histopathologic diagnosis 60 hemorrhagic complications 60 chronic thromboembolic pulmonary 60 cutaneous melanoma 60 pharmacodynamic PD 60 Randomized trials 59 MYCN amplification 59 ventricular dysfunction 59 warfarin therapy 59 Histopathologic 59 prostate cancer CRPC 59 SUVmax 59 Neuradiab 59 hsCRP 59 ARB telmisartan 59 EGFR mutations 59 EDEMA3 trial 59 fluorodeoxyglucose positron emission tomography 59 dopaminergic therapy 59 adolescent idiopathic scoliosis 59 everolimus eluting stents 59 nonoperative treatment 59 coagulation abnormalities 59 non squamous histology 59 IPAH 59 deCODE BreastCancer TM 59 thrombotic complications 59 HeFH 59 neoplasia 59 CHADS2 59 fetal echocardiography 59 antihypertensive therapy 59 rebleeding 59 precursor lesions 59 mediastinal 59 APACHE II 59 cerebral vasospasm 59 systemic amyloidosis 59 metastatic gastric 59 tumor biopsies 59 duplex ultrasonography 59 histologic subtypes 59 tumorigenicity 59 lymphoma subtypes 59 HER2 overexpression 59 thromboembolic disease 59 antibiotic regimens 59 Severe Primary IGFD 59 malignant neoplasms 59 acute coronary syndromes ACS 59 carotid plaque 59 ductal carcinomas 59 visceral metastases 59 MetS 59 antidiabetic drugs 59 spontaneous regression 59 Secondary efficacy endpoints 59 squamous histology 59 Univariate 59 Aspergillus infections 59 perioperative complications 59 non metastatic osteosarcoma 59 univariate analysis 59 molecular biomarkers 59 RRM1 59 CD# expression [002] 59 atherothrombotic disease 59 beta blocker therapy 59 computed tomography angiography 59 osteosarcomas 59 cTnI 59 Histological 59 vWD 59 indolent lymphomas 59 ER CHOP 59 relapsed SCLC 59 metaanalysis 59 nephrogenic 59 Heritability 59 immunohistochemical staining 59 nonfasting triglyceride levels 59 grade cervical intraepithelial 59 lipid abnormalities 59 Acute Coronary Syndromes ACS 59 cardiac troponin 59 occlusive disease 59 posttransplant 59 revascularization procedure 59 Common Toxicity Criteria 59 PAOD 59 etiologic factors 59 adjuvant chemotherapy 59 ductal breast cancer 59 cardiac perfusion 59 comorbid disorders 59 ablative therapy 59 EndoTAGTM 1 59 p# biomarkers 59 direct thrombin inhibitors 59 OnDose TM 59 noncardiac 59 mutated K ras 59 LV ejection fraction 59 pituitary adenomas 59 pyridostigmine 59 recurrent venous thromboembolism 59 aldosterone antagonist 59 anti angiogenic agents 59 ConclusionThis 59 KRAS mutations occur 59 neoadjuvant 59 radical nephrectomy 59 transient elastography 59 immunohistochemical analysis 59 HCV SPRINT 59 renal carcinoma 59 sonographic findings 59 CR nPR 59 morphologic 59 metastatic HRPC 59 Helicobacter pylori eradication 59 central corneal thickness 59 adjuvant radiotherapy 59 prostate carcinogenesis 59 hematologic toxicity 59 death reinfarction 59 systemic lupus erythematosus 59 nonpharmacologic 59 underwent coronary angiography 59 perinatal outcomes 59 arthrography 59 cutaneous squamous cell carcinoma 59 pre malignant lesions 59 thromboembolic 59 SYNTAX 59 palliative radiotherapy 59 myelofibrosis polycythemia vera 59 medically inoperable 59 cartilage lesions 59 osteochondromas 59 axillary dissection 59 immunosuppressive regimens 59 cytogenic 59 Preoperatively 59 lung metastasis 59 fallopian tube carcinoma 59 Secondary endpoints 59 liposomal doxorubicin 59 systolic hypertension 59 gemcitabine Gemzar 59 overt nephropathy 59 HoFH 59 Neovascular AMD 59 mTOR inhibition 59 multivariable adjusted 59 ß blockers 59 sirolimus eluting stents 59 IGRAs 59 hemodynamically significant 59 Haptoglobin 59 glaucomatous 59 Immunohistochemistry 59 Charlson comorbidity index 59 Coronary artery bypass grafting 59 NSCLC tumors 59 cancer mCRC 59 grade cervical dysplasia 59 Hodgkin lymphoma HL 59 carcinoid 59 contrast induced nephropathy 59 Endothelial dysfunction 59 residual confounding 59 thromboprophylaxis 59 cystoscopic 59 Kaplan Meier method 59 postoperative delirium 59 CRp 59 pharmacodynamic endpoints 59 BPH LUTS 59 radiation dosimetry 59 alemtuzumab treated 59 Preoperative 59 poor metabolizers 59 perioperatively 59 pathologic examination 59 mitochondrial toxicity 59 nomogram 59 hematologic disorders 59 neurologic complications 59 heparin induced thrombocytopenia 59 glycoprotein IIb IIIa inhibitors 59 lung nodule 59 Postoperative complications 59 serum phosphate 59 postoperative morbidity 59 pharmacologic intervention 59 carotid artery stenting 59 relapsed ALL 59 Akt activation 59 chronicity 59 methotrexate monotherapy 59 comorbid illnesses 59 atrioventricular block 59 sentinel lymph node biopsy 59 hepatocellular cancer 59 somatostatin analogs 59 immunohistochemical 59 CIN3 59 observational cohort study 59 histologically proven 59 stage IIIA 59 tolerability pharmacokinetics 59 squamous cell lung cancer 59 virologic responses 59 elevated bilirubin 59 APPRAISE 59 serous ovarian cancer 59 vismodegib 59 nonmetastatic prostate cancer 59 gene polymorphisms 59 GH deficiency 59 Papillary 59 metachronous 59 antiphospholipid syndrome 59 renal artery stenosis 59 genomewide 59 concomitant AEDs 59 Retreatment 59 echocardiographic 59 anti angiogenic drugs 59 macrovascular events 59 unfavorable cytogenetics 59 sipuleucel T 59 underlying pathophysiology 59 antioxidant supplementation 59 cerebral perfusion 59 minimally symptomatic 59 revascularization procedures 59 microscopic hematuria 59 neuropathologic 59 interrater reliability 59 metaplasia 59 superficial bladder cancer 59 Diabetic nephropathy 59 adnexal mass 59 prophylactic cranial irradiation 59 elevated ALT 59 Framingham Risk Score 59 Index CDAI 59 ruboxistaurin 59 cerebral microbleeds 59 Follicular Lymphoma 59 carcinomatosis 59 seminal vesicle invasion 59 Echocardiographic 59 estimated GFR 59 S. maltophilia 59 ImmuKnow assay 59 radioiodine therapy 59 #F FDG PET CT 59 amnestic MCI 59 secondary efficacy endpoints 59 paragangliomas 59 AGILECT R 58 PREVENT IV 58 contrast echocardiography 58 urothelial 58 cytoreduction 58 perfusion imaging 58 paclitaxel eluting stents 58 Hematologic 58 glial tumors 58 lymphocytosis 58 immune dysregulation 58 MiCK assay 58 serum markers 58 Sjögren syndrome 58 subclinical hypothyroidism 58 cediranib 58 grade glioma 58 nasopharyngeal carcinoma 58 DVT PE 58 p = #.# [003] 58 prognostic 58 Gorlin syndrome 58 hemodynamic variables 58 Liver biopsy 58 CYP#D# genotype 58 CIMZIA ™ 58 arterial calcification 58 mutational status 58 multicenter trials 58 Angiographic 58 myocardial revascularization 58 lesional 58 mTOR inhibitors 58 intratumoral 58 glycated hemoglobin levels 58 urodynamic parameters 58 Coronary artery calcium 58 pT2 58 graft patency 58 MDCT angiography 58 castration resistant prostate cancer 58 molecular subtypes 58 ACCORD Lipid 58 atherosclerotic vascular disease 58 aneurysm rupture 58 anterior uveitis 58 elevated triglyceride levels 58 biologic DMARDs 58 thymoma 58 dose Iluvien 58 Metastatic breast cancer 58 HIPEC 58 lower extremity amputation 58 Computed tomography 58 predictive biomarkers 58 abnormal cytology 58 interferon γ 58 intravenous cyclophosphamide 58 Xanafide 58 acetabular fracture 58 adrenocortical cancer 58 preoperatively 58 miRview ™ squamous 58 psychosocial functioning 58 rFVIIa 58 glomerular filtration rate 58 GPRD 58 COR Analyzer 58 DAS# CRP 58 seminomas 58 mediastinal lymph nodes 58 gp# vaccine 58 esophageal squamous cell carcinoma 58 Mantel Haenszel 58 AVOREN 58 AtherOx 58 asymptomatic carotid stenosis 58 poststroke depression 58 thrombolytic agents 58 urodynamic 58 SCD HeFT 58 neoadjuvant radiation 58 hyperacute 58 PCWP 58 mixed hyperlipidemia 58 arterial thickening 58 breast cancer metastasis 58 coronary anatomy 58 vesicoureteral reflux 58 antiretroviral naïve 58 atherosclerotic lesions 58 airway hyperresponsiveness 58 MADIT II 58 Ejection Fraction 58 tumor hypoxia 58 left ventricular LV 58 BioMAP 58 adnexal masses 58 PROSTVAC ® 58 malignant growths 58 GISTs 58 Observational studies 58 chemoradiation therapy 58 GORE VIABAHN Endoprosthesis 58 diagnosing coronary artery 58 immunochemical fecal occult 58 molecular abnormalities 58 thyrotropin 58 colorectal neoplasms 58 femoral fractures 58 chromosomal mutations 58 functional mitral regurgitation 58 PHPT 58 prospective observational studies 58 Crohn Disease Activity 58 allograft rejection 58 subclinical disease 58 adenotonsillectomy 58 HRQOL 58 aromatase inhibitor therapy 58 myeloproliferative neoplasms 58 adjuvant radiation 58 Circulating tumor cells